Bluebird falls as FDA weighs cancer risks of co's gene therapy

bluebird bio

27/11/2024 18:35

** Shares of gene therapy developer bluebird bio  BLUE.O 
fall 1.8% to 36 cents; set to snap a three-day winning streak
    ** The U.S. FDA says it is weighing the need of regulatory
action on BLUE's gene therapy, Skysona, used to treat a rare
neurological disorder called cerebral adrenoleukodystrophy 
    ** Additional cases of serious blood cancers reported in
patients treated with Skysona, FDA says; therapy's prescribing
information already warns of those risks
    ** FDA advises exploring alternative therapies before using
Skysona, considering the risk of blood cancers
    ** Including session's gains, stock has fallen 73.6% YTD and
has been trading below the $1-mark since mid-August 

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))